Improving Access to Overdose Treatment (Short Title: OD Treatment Access) | SP 17 006

Opportunity Information: Apply for SP 17 006

The Improving Access to Overdose Treatment grant opportunity (short title: OD Treatment Access) is a discretionary federal grant offered by the U.S. Department of Health and Human Services through SAMHSA, specifically SAMHSA's Center for Substance Abuse Prevention (CSAP). The core purpose of the program is to reduce opioid overdose deaths and serious overdose-related harms by expanding timely access to FDA-approved overdose reversal drugs or devices used for the emergency treatment of known or suspected opioid overdose. In practice, this centers on getting proven overdose-reversal interventions into more clinical and community settings, improving how clinicians prescribe and co-prescribe these products, and making sure people who are at high risk of overdose, as well as those who support them, are trained to respond effectively.

Funding is targeted to a single award in FY 2017, with an anticipated award ceiling of $1,000,000. SAMHSA designed the program to support one lead organization or practitioner that can serve as a hub for community-level coordination and training. Eligible applicants are limited to a Federally Qualified Health Center (FQHC), an Opioid Treatment Program, or an individual practitioner who holds a waiver to prescribe buprenorphine. This eligibility focus reflects the program's intent to anchor overdose response improvements in settings that either already treat opioid use disorder directly or have the legal and clinical capacity to connect overdose survivors to evidence-based treatment, including medication-assisted treatment.

A central expectation of the grant is partnership and standard-setting. The funded grantee is required to work with other prescribers in the community to develop practical best practices for prescribing and co-prescribing FDA-approved overdose reversal drugs. The emphasis on "co-prescribing" signals an intent to normalize and expand the routine provision of overdose reversal medications alongside opioid prescriptions or when risk factors are present, rather than treating naloxone access as an afterthought or a purely emergency-service function. Once these best practices are created, the grantee must move into broad training activities, targeting other prescribers in key community sectors and also training individuals who support people at high risk for overdose. This can include clinicians outside specialty addiction care, as well as non-clinical supporters who are likely to be present when an overdose occurs.

The program explicitly builds on SAMHSA's 2013 Opioid Overdose Prevention Toolkit, which was developed to help communities and providers reduce opioid-related overdose deaths and adverse events. The grant requires grantees to use the toolkit and related resources to train and equip health care providers and pharmacists on prescribing drugs or devices that are approved or cleared under the Federal Food, Drug, and Cosmetic Act for emergency overdose treatment. This component highlights that the opportunity is not only about purchasing or distributing products; it is also about changing practice patterns and improving provider and pharmacist readiness through structured guidance, education, and dissemination of standardized protocols and materials.

Another major requirement is the creation of protocols that connect people who have experienced an overdose to ongoing care. SAMHSA is not treating overdose reversal as the endpoint; instead, the grant frames an overdose event as a critical intervention point where rapid linkage to treatment can save lives. Grantees are expected to establish processes to ensure that overdose survivors are referred and connected to appropriate treatment services, including medication-assisted treatment and appropriate counseling and behavioral therapies. This linkage-to-care element is meant to close a common gap where individuals are revived in an emergency setting but do not receive follow-up addiction treatment, increasing the risk of repeated overdose.

Administratively, the opportunity is identified as Funding Opportunity Number SP 17 006 under CFDA 93.243, categorized under the health funding activity area, and uses the grant funding instrument. The opportunity was created on May 31, 2017, with an original application closing date of July 31, 2017. Overall, OD Treatment Access is structured as a focused, high-impact award intended to strengthen local systems for overdose prevention and response by improving prescribing norms, expanding training across medical and community stakeholders, and building reliable pathways from overdose reversal to evidence-based treatment and recovery supports.

• The Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis in the health sector is offering a public funding opportunity titled "Improving Access to Overdose Treatment (Short Title: OD Treatment Access)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.243.
• This funding opportunity was created on May 31, 2017.
• Applicants must submit their applications by Jul 31, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).

Apply for SP 17 006

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: